BofA/Merrill Lynch Downgrades Dr. Reddy's Laboratories (RDY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq climb as soft inflation dampens Fed rate hike expectations
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 flat as higher bond yields counter tech optimism
Dr. Reddys Labs (RDY) Reports Q3 EPS of $0.40
February 14, 2013 6:54 AM ESTDr. Reddys Labs (NYSE: RDY) reported Q3 EPS of $0.40, versus $0.50 reported last year. Revenue for the quarter came in at $522 million, versus $505 million reported last year.
For earnings history and earnings-related data on Dr. Reddys Labs (RDY) click here.... More
